Gene therapy restores vision in a canine model of childhood blindness
- PMID: 11326284
- DOI: 10.1038/ng0501-92
Gene therapy restores vision in a canine model of childhood blindness
Abstract
The relationship between the neurosensory photoreceptors and the adjacent retinal pigment epithelium (RPE) controls not only normal retinal function, but also the pathogenesis of hereditary retinal degenerations. The molecular bases for both primary photoreceptor and RPE diseases that cause blindness have been identified. Gene therapy has been used successfully to slow degeneration in rodent models of primary photoreceptor diseases, but efficacy of gene therapy directed at photoreceptors and RPE in a large-animal model of human disease has not been reported. Here we study one of the most clinically severe retinal degenerations, Leber congenital amaurosis (LCA). LCA causes near total blindness in infancy and can result from mutations in RPE65 (LCA, type II; MIM 180069 and 204100). A naturally occurring animal model, the RPE65-/- dog, suffers from early and severe visual impairment similar to that seen in human LCA. We used a recombinant adeno-associated virus (AAV) carrying wild-type RPE65 (AAV-RPE65) to test the efficacy of gene therapy in this model. Our results indicate that visual function was restored in this large animal model of childhood blindness.
Similar articles
-
Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy.Prog Retin Eye Res. 2010 Sep;29(5):398-427. doi: 10.1016/j.preteyeres.2010.04.002. Epub 2010 Apr 24. Prog Retin Eye Res. 2010. PMID: 20399883 Free PMC article. Review.
-
RPE65: role in the visual cycle, human retinal disease, and gene therapy.Ophthalmic Genet. 2009 Jun;30(2):57-62. doi: 10.1080/13816810802626399. Ophthalmic Genet. 2009. PMID: 19373675 Free PMC article. Review.
-
Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation.PLoS Med. 2007 Jun;4(6):e230. doi: 10.1371/journal.pmed.0040230. PLoS Med. 2007. PMID: 17594175 Free PMC article.
-
Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis.Hum Gene Ther. 2006 Aug;17(8):845-58. doi: 10.1089/hum.2006.17.845. Hum Gene Ther. 2006. PMID: 16942444
-
Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness.Mol Ther. 2005 Dec;12(6):1072-82. doi: 10.1016/j.ymthe.2005.08.008. Epub 2005 Oct 14. Mol Ther. 2005. PMID: 16226919 Free PMC article.
Cited by
-
Manifestations of systemic disease in the retina and fundus of cats and dogs.Front Vet Sci. 2024 Feb 20;11:1337062. doi: 10.3389/fvets.2024.1337062. eCollection 2024. Front Vet Sci. 2024. PMID: 38444779 Free PMC article. Review.
-
Seeing the Future: A Review of Ocular Therapy.Bioengineering (Basel). 2024 Feb 13;11(2):179. doi: 10.3390/bioengineering11020179. Bioengineering (Basel). 2024. PMID: 38391665 Free PMC article. Review.
-
Cone-Driven, Geniculocortical Responses in Canine Models of Outer Retinal Disease.Transl Vis Sci Technol. 2024 Jan 2;13(1):18. doi: 10.1167/tvst.13.1.18. Transl Vis Sci Technol. 2024. PMID: 38241039 Free PMC article.
-
The Use of rAAV2-RB1-Mediated Gene Therapy in Retinoblastoma.Invest Ophthalmol Vis Sci. 2023 Dec 1;64(15):31. doi: 10.1167/iovs.64.15.31. Invest Ophthalmol Vis Sci. 2023. PMID: 38133505 Free PMC article.
-
Treatment Strategy With Gene Editing for Late-Onset Retinal Degeneration Caused by a Founder Variant in C1QTNF5.Invest Ophthalmol Vis Sci. 2023 Dec 1;64(15):33. doi: 10.1167/iovs.64.15.33. Invest Ophthalmol Vis Sci. 2023. PMID: 38133503 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials